News

By The Medicine Maker
September 4, 2025 – CAR T Vision is guided by a Steering Committee of leaders from prominent patient advocacy groups across Europe and North America, medical societies, treatment centers, and other subject matter experts. The initiative launched in early 2025 with initial funding and support from Gilead and Kite.

By Drug Discovery World July 1, 2025 – CAR T Vision has launched to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR-T therapy. By 2030, the coalition aims to double the proportion of eligible patients treated with CAR-T therapy.   As outlined in a new roadmap […]

By Pharmalive.com June 16, 2025 – CAR T-cell therapy represents one of the most transformative advances in cancer treatment over the past decade, offering hope for durable remissions and potential cure in patients with certain aggressive and advanced blood cancers. But despite its promise — and more than seven years of availability in the United […]

May 30, 2025, Chicago – Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care.